Stress, lack of sleep, and constant interruptions make spending time in the hospital physically and emotionally exhausting. But for me, it's just as difficult to come home from a hospital stay and get back to “real life.”
Site Search
Just in time for Valentine's Day, we take a minute to look back on our top three picks for the most romantic blog posts last year.
Sending your child to kindergarten for the first time is hard enough, but when your child has cystic fibrosis, it is even harder. Here's how I handled my daughter's transition to kindergarten and the lessons I learned along the way.
The initial sadness we felt when learning that our son had cystic fibrosis quickly gave way to our determination -- as a family -- to react in a productive way.
With several successes for the cystic fibrosis community over the past several months, advocacy is as important as ever to preserving our progress and working toward a cure.
On July 9, the Cystic Fibrosis Foundation's President and CEO, Dr. Michael P. Boyle, participated in the global launch of the AMR Action Fund. Alongside leaders in global health, Dr. Boyle highlighted the critical need of antibiotics for people living with CF and stressed that research investment alone will not solve the challenges of antibiotic development.
After our son Sam died in 1990, I felt a kinship to everyone impacted by cystic fibrosis. I knew they could understand what we'd been through: parenting and losing a very special human being we loved so deeply.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).
The Cystic Fibrosis Foundation today announced an unprecedented acceleration and expansion of its research, care and patient programs for the CF community. This action is possible as a result of the sale of the Foundation's royalty rights to CF treatments developed by Vertex Pharmaceuticals Inc. The Foundation received $3.3 billion from the sale to Royalty Pharma.